Tag Archives: TreatmentResistant

FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression

Print this page March 5, 2019 — The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting… Read More »

FDA Approves Johnson & Johnson’s Ketamine-Derived Drug For Treatment-Resistant Depression

More than 16 million Americans experience depression and an estimated 30 to 40% are not helped by first-line treatments including antidepressants and psychotherapy. Getty The U.S. Food & Drug Administration Tuesday approved Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression. The green light means ketamine—an anesthetic abused as a party drug but promoted… Read More »